Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Dregan, Alexa; * | Chowienczyk, Philb | Gulliford, Martin C.a
Affiliations: [a] King’s College London, Department of Primary Care and Public Health Sciences, London, UK and NIHR Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust, London, UK | [b] King’s College London, British Heart Foundation Centre, London, UK
Correspondence: [*] Correspondence to: Alex Dregan, PhD, King’s College London, Department of Primary Care and Public Health, 6th Floor, Capital House, 42 Weston Street, London SE1 3QD, United Kingdom. Tel.: +44 207 8486639; Fax: +44 207 8486620; alexandru.dregan@kcl.ac.uk
Abstract: Background: There is limited primary-care based evidence for an association between chronic inflammation and related therapy with all-cause dementia. Objective: To estimate the association between several chronic inflammatory disorders and related drug therapy and all-cause dementia. Methods: The study population included a cohort of patients diagnosed with inflammatory conditions and matching controls (ratio 1:2) from the Clinical Practice Research Datalink, a database or primary care records in the UK. Inflammation patients and controls were matched on age, gender, and family practice. The study outcome measure was all-cause dementia. Chronic inflammation diagnosis and anti-inflammatory drugs represented the exposure variables of interest. Competing risks analyses were used to estimate the risk of dementia associated with exposure variables. Results: There were 1,378 (1% ) and 2,805 (1% ) dementia events recorded for chronic inflammation patients and their matched controls, respectively. Systemic vasculitis was associated with increased hazard ratios of dementia (1.75, 95% confidence interval (CI) 1.35–2.27, p < 0.001). The analyses revealed increased risk of dementia for systemic vasculitis (1.64, 95% CI 1.24–2.18), Crohn’s diseases (2.08, 95% CI 1.16–3.74), bullous skin diseases (1.55, 95% CI 1.11–2.18), and inflammatory arthritis (1.33, 95% CI1.06–1.63) among treated patients. Combined glucocorticoids and NSAID therapy suggested reduced risk of dementia across most conditions, particularly systemic autoimmune disorders (0.41, 95% CI 0.18–0.95). Conclusion: The association between chronic inflammation and dementia varied across inflammatory disorders, being stronger for systemic vasculitis. There was evidence that combined therapy was associated with lower risk of dementia across most disorders. These data highlight potential avenues for future mechanistic and intervention investigations.
Keywords: Chronic inflammation, dementia, glucocorticoids, NSAIDs, primary care
DOI: 10.3233/JAD-150171
Journal: Journal of Alzheimer's Disease, vol. 46, no. 4, pp. 1039-1047, 2015
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl